The role of neurotensin in central nervous system pathophysiology: What is the evidence?

The role of neurotensin in central nervous system pathophysiology: What is the evidence?

PDF

J Psychiatry Neurosci 2006;31(4):229-45

Fannie St-Gelais, MSc; Claudia Jomphe, MSc; Louis-Éric Trudeau, PhD

St-Gelais, Jomphe, Trudeau — Department of Pharmacology; Trudeau — Centre de recherche en sciences neurologiques, Faculty of Medicine, Université de Montréal, Montréal, Que.

Abstract

The peptide neurotensin has been studied for more than 30 years. Although it is widely distributed in the central and peripheral nervous systems, neurotensin has been more intensely studied with regard to its interactions with the central dopamine system. A number of claims have been made regarding its possible implication in many diseases of the central nervous system, including schizophrenia. In this review, we describe briefly the basic biology of this neuropeptide, and then we consider the strengths and the weaknesses of the data that suggest a role for neurotensin in schizophrenia, drug abuse, Parkinson’s disease, pain, central control of blood pressure, eating disorders, cancer, neurodegenerative disorders and inflammation.

Résumé

Le peptide neurotensine est l’objet d’études depuis plus de 30 ans. La neurotensine est largement distribuée dans les systèmes nerveux central et périphérique, mais ses interactions avec le système de neurotransmission dopaminergique central ont été les plus étudiées. On a formulé plusieurs suggestions quant à son intervention dans diverses maladies du système nerveux central, telles que la schizophrénie. Dans cette revue de la littérature, nous débutons par une brève description de la biologie de ce neuropeptide, puis nous examinons les forces et les faiblesses des données relatives aux implications de la neurotensine dans la schizophrénie, la dépendance aux drogues, la maladie de Parkinson, la douleur, le contrôle central de la pression artérielle, les troubles de l’alimentation, le cancer, les maladies neurodégénératives et l’inflammation.


Medical subject headings: central nervous system; dopamine; neurotensin; Parkinson disease; pathophysiology; schizophrenia

Competing interests: None declared.

Contributors: All authors contributed to the conception and design of the review, analyzed the data, wrote and reviewed the article, and gave final approval for publication.

Submitted Dec. 1, 2005; Revised Jan. 26, 2006; Jan. 30, 2006; Accepted Jan. 30, 2006

Correspondence to: Dr. Louis-Éric Trudeau, Department of Pharmacology, Faculty of Medicine, Université de Montréal, C.P. 6128, Succursale Centre-ville, Montréal QC H3C 3J7; fax 514 343-2291; louis-eric.trudeau@umontreal.ca